Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-27, FY ended December 31, 2025) + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP — Unqualified opinion
One-line verdict: IFF is a post-merger restructuring story that has not yet delivered. The company reported a net loss of $361 million in FY2025, including a $1.153 billion goodwill impairment in its Food Ingredients segment triggered by a segment reorganization. Goodwill plus intangibles at 101% of equity exceeds total shareholders' equity — a direct consequence of the 2021 DuPont Nutrition & Biosciences merger that transformed IFF into a heavily indebted conglomerate. Cash covers only 9% of $6.6B debt, Debt/EBITDA is 8.5x, the Z-Score sits in the grey zone at 1.25, and IFF has reported net losses in three of the last four years. The company is aggressively divesting to delever — selling Pharma Solutions, Nitrocellulose, and Cosmetic Ingredients businesses — but the path to financial health remains long.
| Metric | Result |
|---|---|
| Red Flags | **2** (cash-to-debt, goodwill/equity) |
| Watch Items | **3** (CapEx surge, CFFO/NI, leverage) |
| Checks Completed | **17/18** (1 N/A: impairment data) |
| Beneish M-Score | **-2.54** (clean) |
| Z-Score | **1.25** (grey zone) |
| Auditor | PricewaterhouseCoopers LLP |
Two Segments After Reorganization
Effective January 1, 2025, IFF reorganized from four segments to two:
| Segment | FY2025 Net Sales | Description |
|---|---|---|
| Taste | $2,481M | Flavor compounds, natural taste solutions |
| Food Ingredients | ~$8,409M | Functional ingredients, texturants, cultures, enzymes |
Per the filing: "Net sales were $10,890 million" for FY2025, down from $11,484M in FY2024 (-5.2%). The reorganization triggered a goodwill impairment test that revealed the Food Ingredients segment's fair value was below carrying value.
Key financial metrics from the filing:
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Net (loss) income attributable to IFF | ($361M) | $263M | ($2,591M) |
| EPS (diluted) | ($1.41) | $1.04 | ($10.14) |
| Gross margin | 36.2% | 35.9% | 32.1% |
| R&D as % of sales | 6.4% | 5.8% | 5.5% |
Three of the last four years have produced net losses. Only FY2024 was profitable, and even that at a razor-thin $263M on $11.5B revenue.
Cash Flow: Weak and Deteriorating
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $1,455M | $1,070M | $850M |
| Net Income (loss) | -$2,591M | $263M | -$361M |
| CFFO / NI | -0.56 | 4.07 | -2.35 |
| CapEx | $503M | $468M | $596M |
| Free Cash Flow | $952M | $602M | $254M |
Per the filing: "Cash flows provided by operating activities in 2025 were $850 million, or 7.8% of sales, compared to $1.070 billion, or 9.3% of sales, in 2024. The decrease in cash flows from operating activities from 2024 to 2025 was primarily driven by an increase in working capital and a larger incentive compensation payout."
FCF collapsed from $952M to $254M over two years. Depreciation and amortization was $962M — a massive non-cash expense from the N&B merger intangibles that are amortizing through the income statement.
Divestiture proceeds are the primary deleveraging mechanism. The filing references the Pharma Solutions sale (closed May 2025) and Nitrocellulose business divestiture, plus the 2024 Cosmetic Ingredients divestiture.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | ✅ | DSO 58 days, +6 days YoY |
| A2 | AR vs Revenue Growth | ✅ | AR growth +6.6% vs revenue -5.2% |
| A3 | Revenue vs CFFO | ✅ | Revenue -5.2%, CFFO -20.6% |
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | ✅ | Inventory +4.8% vs COGS -5.5% |
| B2 | CapEx vs Revenue | ⚠️ | CapEx growth 27.4% vs revenue -5.2% |
| B3 | SG&A Ratio | ✅ | SG&A/Gross Profit = 46.6% |
| B4 | Gross Margin | ✅ | 36.2%, +0.3pp |
B2 — CapEx increasing while revenue declines. CapEx rose from $468M to $596M (+27.4%) even as revenue fell 5.2%. This suggests the company is investing in infrastructure for its remaining portfolio, but the divergence with revenue is concerning for a company with thin cash flow.
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | ⚠️ | CFFO/NI = -2.35 (net loss year) |
| C2 | Free Cash Flow | ✅ | FCF $254M, FCF/NI = -0.70 |
| C3 | Accruals Ratio | ✅ | -4.7%. Clean |
| C4 | Cash vs Debt | ❌ | Cash $0.6B covers only 9% of debt $6.6B |
C4 — Critical liquidity concern. Cash of $590M against total debt of $6,619M. Per the filing: "total debt was approximately $5.994 billion" (net of adjustments), and the company faces "pricing grids tied to our credit ratings, and financial covenants under our revolving credit facility." IFF has been actively deleveraging — debt fell from $10.8B (FY2023) to $9.6B (FY2024) to $6.6B (FY2025) — but cash is dangerously low at $590M.
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | ❌ | $14.3B = 101% of equity |
| D2 | Leverage | ⚠️ | Debt/EBITDA = 8.5x |
| D3 | Soft Asset Growth | ✅ | Other assets +6.2% vs revenue -5.2% |
| D4 | Asset Impairment | — | No write-off data |
D1 — Goodwill exceeds equity. At 101% of equity, goodwill and intangibles represent the entirety of IFF's book value. The $1.153 billion impairment recorded in FY2025 demonstrates the fragility: per the filing, "we recorded an impairment charge of $1.153 billion within the Food Ingredients operating segment as a result of the change in the Company's segments." Any further impairment could drive equity negative.
D2 — Elevated leverage. Debt/EBITDA of 8.5x is well above the 4x warning threshold. The filing warns about covenant compliance: "Revolving credit agreement contains various covenants, limitations and events of default."
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | ✅ | FCF after acquisitions positive |
| E2 | Goodwill Surge | ✅ | Goodwill -8% YoY (impairment-driven) |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | ✅ | -2.54 (clean) |
The DEPI (Depreciation Index) at 1.101 reflects declining depreciation rates as intangibles amortize. All other components are benign.
Key Risks from the 10-K
1. $1.153 Billion Goodwill Impairment — Segment Reorganization Triggered Write-Down
Per the filing: "As a result of the segment reorganization that occurred on January 1, 2025, goodwill related to the former Nourish reporting unit was allocated between the Taste and Food Ingredients reporting units." The impairment test revealed that Food Ingredients' fair value was below its carrying amount. The filing warns: "Any future restructuring or other changes" could trigger additional impairments.
2. Antitrust Class Action Litigation
The filing references an "Antitrust Class Action" filed on November 17, 2025. Details are limited in the XBRL data, but antitrust exposure in the flavors and fragrances industry could result in material fines or settlements.
3. Continued Divestiture Execution Risk
IFF is selling businesses to delever. The "Loss on assets classified as held for sale was $115 million in 2025" — meaning divestitures are being completed at losses. If remaining businesses sell below book value, additional write-downs could erode equity further.
4. Declining Revenue Despite Stable Market
Revenue fell from $12.4B (2022) to $10.9B (2025) — a 12% decline over three years, partly from divestitures but also from organic weakness. The company's ability to grow the remaining portfolio is unproven.
Summary
Grade: F. A post-merger restructuring play where the 2021 N&B acquisition created a debt-laden conglomerate that has reported net losses in three of four years, recorded $1.15B in goodwill impairment, and carries goodwill exceeding total equity.
IFF's $26B acquisition of DuPont's Nutrition & Biosciences division in 2021 was transformational but has not yet delivered financial stability. Debt has been reduced from $11.7B to $6.6B through divestitures, but operating cash flow has simultaneously declined from $1.5B to $850M. Goodwill at 101% of equity, Debt/EBITDA of 8.5x, cash at 9% of debt, and three net loss years in four make this one of the most financially stressed companies in this batch. The M-Score passes at -2.54 — the books are not being manipulated — but the underlying business has not yet stabilized from the merger integration.
**Disclaimer**: This report is based on IFF's FY2025 10-K filed with SEC EDGAR on February 27, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP (Unqualified opinion)
Fiscal year ended: December 31, 2025